Mechanisms of Acquired Resistance in First-Line Treatment – Amivantamab plus Lazertinib vs. Osimertinib

During a Case-Based Roundtable® event, Chul Kim, MD, moderated a discussion on current use of ALK TKIs in lung cancer in the second article of a 2-part series.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed hope to millions worldwide.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival.